Trending...
- National Sign Company, Philadelphia Sign Company, to Attend Bank Facilities Forum
- eCaregivers Launches First-Ever Consumer-Driven Senior Care Platform for Private-Pay Home Care Offering Affordable, Full-Service Agency Experience
- Launch of the Theory of Adaptive Synthesis in Business Operations
EAST RUTHERFORD, N.J., Sept. 19, 2024 ~ Cambrex, a global contract development and manufacturing organization (CDMO), has recently announced a breakthrough in peptide synthesis technology. The company's subsidiary, Snapdragon Chemistry, has successfully developed a new liquid-phase peptide synthesis (LPPS) technology that eliminates the need for specialized solid-phase reactors.
This innovative LPPS technology utilizes traditional active pharmaceutical ingredient (API) batch reactors and continuous flow, significantly reducing solvent demand and excess reagents compared to standard solid-state peptide synthesis processes. This not only makes the process more cost-efficient but also more environmentally sustainable.
Dr. Matt Bio, Chief Scientific Officer at Cambrex, stated that the company has been investing in research and development of complex synthetics for several years with the goal of reducing economic and environmental impacts in peptide and oligonucleotide manufacturing. He added that their new LPPS technology offers a more efficient and sustainable solution compared to traditional methods.
More on Jersey Desk
The LPPS technology can support peptides up to 12 residues long, while larger peptides can be assembled using a convergent fragment coupling approach in liquid phase. This allows for scalability similar to traditional small molecules.
In addition to LPPS, Cambrex has also developed unique capabilities in peptide and protein crystallization. They have a screening platform specifically designed for discovering crystalline forms of peptides and proteins. Crystallization can improve product quality and stability while reducing the need for time-consuming preparative chromatography and lyophilization.
Thomas Loewald, CEO at Cambrex, emphasized the importance of providing industry-leading solutions for developing and scaling peptide-based therapies. He stated that their continued investment in R&D across complex synthetic modalities will include further technology development for peptides as well as research on the application of artificial intelligence in optimizing oligonucleotide processes.
Cambrex's new LPPS technology is expected to have a significant impact on the pharmaceutical industry by offering a more efficient and sustainable method for synthesizing peptides. With their continued investment in research and development, the company is poised to remain a leader in complex synthetic modalities.
This innovative LPPS technology utilizes traditional active pharmaceutical ingredient (API) batch reactors and continuous flow, significantly reducing solvent demand and excess reagents compared to standard solid-state peptide synthesis processes. This not only makes the process more cost-efficient but also more environmentally sustainable.
Dr. Matt Bio, Chief Scientific Officer at Cambrex, stated that the company has been investing in research and development of complex synthetics for several years with the goal of reducing economic and environmental impacts in peptide and oligonucleotide manufacturing. He added that their new LPPS technology offers a more efficient and sustainable solution compared to traditional methods.
More on Jersey Desk
- Ocean Partnership for Children to Host 5th Annual Candlelight Vigil
- OpsVeda Is Now Available Through AWS Marketplace
- Circumference Group Acquires Majority Stake in Visionary Integration Professionals
- Tim O'Loughlin Appointed Chief Executive Officer of Vantiva and Co-opted as a Director of the Board
- TN Nursery Gears Up for Busy Fall Shipping Season with Nationwide Fast Shipping, Low Grower Prices, and Storewide Deals
The LPPS technology can support peptides up to 12 residues long, while larger peptides can be assembled using a convergent fragment coupling approach in liquid phase. This allows for scalability similar to traditional small molecules.
In addition to LPPS, Cambrex has also developed unique capabilities in peptide and protein crystallization. They have a screening platform specifically designed for discovering crystalline forms of peptides and proteins. Crystallization can improve product quality and stability while reducing the need for time-consuming preparative chromatography and lyophilization.
Thomas Loewald, CEO at Cambrex, emphasized the importance of providing industry-leading solutions for developing and scaling peptide-based therapies. He stated that their continued investment in R&D across complex synthetic modalities will include further technology development for peptides as well as research on the application of artificial intelligence in optimizing oligonucleotide processes.
Cambrex's new LPPS technology is expected to have a significant impact on the pharmaceutical industry by offering a more efficient and sustainable method for synthesizing peptides. With their continued investment in research and development, the company is poised to remain a leader in complex synthetic modalities.
Filed Under: Business
0 Comments
Latest on Jersey Desk
- Voices Rising Festival Celebrates Diversity in E. Islip, GRAMMY Governor LACHI performs!
- VSA Officially Receives SOC 2 Approval
- SeaCube Container Leasing Adds to its Board of Directors
- Martial Arts Icon Cynthia Rothrock Premieres Her Latest Film Black Creek
- Vantiva and Harmonic Partner to Offer Service Providers Easy Transition from DOCSIS to Fiber-based PON Technologies
- CCHR Demands Justice for Victims of Psychiatric Fraud and Patient Sexual Abuse
- 9/11 Memorial Unveiled in Chesterfield, NJ, and National Day of Service Commemorated in Milpitas, CA
- First World Chronic Cough Day October 15, 2024
- New Frontier Aerospace Closes Seed Round with Pacific Bays Capital
- MMCG Invest and Innowave Studio Merge to Revolutionize Feasibility Studies and Site Plans
- Affluent New York City Suburbs Now Have Access to Private Client Health & Wellness via CourMed
- State of Nayarit Named the Official Mexican Tourism Destination of the Vancouver Canucks
- WLKATA Mirobot Fruit Picking Cell: Pioneering Project-Based Learning in Smart Farming
- ProtectVirginia Petitions Virginia Dept of Environmental Quality for Cruise Ship Regulations
- Campaign for Kindness: Floris UMC is bringing back respect, humility, and compassion this election season
- Situ Ve Offers a New Perspective on Love Amid the Rising Passport Bro Movement
- Launch of the Theory of Adaptive Synthesis in Business Operations
- Scout & Cellar Becomes First Winery in Texas to Receive B Corp Certification
- CRH Healthcare Acquires Four Urgent Care Clinics in Georgia
- eCaregivers Launches First-Ever Consumer-Driven Senior Care Platform for Private-Pay Home Care Offering Affordable, Full-Service Agency Experience